Related Experiment Video
Updated: Jun 13, 2025
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
Adiposity Rebound Timing in Small for Gestational Age Children Treated With Growth Hormone: Results From LG Growth
Ji Hyun Kim1, Su Jin Kim2, In Hyuk Chung3
1Department of Pediatrics, Dongguk University Ilsan Hospital, Goyang, Korea.
Insights
Adiposity rebound (AR) in children born small for gestational age (SGA) without catch-up growth occurs later than in the general population. AR timing did not significantly impact puberty onset or growth outcomes in this cohort.
Area of Science:
- Pediatrics
- Endocrinology
- Growth and Development
Background:
- Adiposity rebound (AR) is a critical growth phase linked to obesity and puberty.
- Limited research exists on AR timing in Korean children born small for gestational age (SGA).
Purpose of the Study:
- Determine AR timing in SGA children without catch-up growth (CUG) treated with growth hormone (GH).
- Identify factors influencing AR timing.
- Examine AR's impact on puberty onset and GH therapy effectiveness.
Main Methods:
- Analysis of data from the LG Growth Study, a multicenter observational clinical trial.
- Inclusion of 151 prepubertal children born SGA without CUG.
- Assessment of AR timing, puberty onset, and GH therapy outcomes.
Main Results:
- 15% of children had AR aged 4-5, 42% aged 5-6, 27% aged 6-7, and 16% after 7.
- A positive correlation was found between initial height SDS and AR timing.
- No significant correlation between AR timing and puberty onset or GH therapy effectiveness.
Conclusions:
- AR in SGA children without CUG appears to occur later than in the general population.
- AR timing in this cohort shows no significant relationship with puberty onset or growth outcomes.
- Provides insights into AR timing and growth in specific SGA populations.
Background:
Adiposity rebound (AR) refers to the period during growth when the body mass index reaches its lowest point before increasing again. The timing of AR is associated with the development of obesity and puberty onset. Although studies have evaluated AR timing in Korean children, none has focused on children born small for gestational age (SGA).
Methods:
This study analyzed data from a multicenter observational clinical trial (LG Growth Study) to determine AR timing in children born SGA without catch-up growth (CUG) who were treated with growth hormone (GH) therapy. The study also aimed to identify factors associated with AR timing, examine the influence of AR timing on puberty onset, and assess the effectiveness of GH therapy.
Results:
A total of 151 children born SGA without CUG were included. Of them, 15% experienced AR between 4 and 5 years of age, 42% between 5 and 6 years, 27% between 6 and 7 years, and 16% after 7 years of age. A significant positive correlation was noted between the height standard deviation score at the start of treatment and AR timing. However, no significant correlation was observed between AR timing and puberty onset or the effectiveness of GH therapy.
Conclusion:
This study provides insights into AR timing in prepubertal children who meet the specific SGA criteria and its relationship with growth outcomes. The findings suggest that AR in children born SGA who do not experience CUG occurs later than in the general population, with no significant relationship between AR timing and puberty onset or growth outcomes.
Trial Registration:
ClinicalTrials.gov Identifier: NCT01604395.
Related Concept Videos
01:27Signs of Puberty
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:10Nature and Nurture
01:15Hypoglycemia and Glucagon
01:24Obesity
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...